A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

scientific article

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/605608
P698PubMed publication ID19712040
P5875ResearchGate publication ID26771978

P50authorEmanuele MontomoliQ43110625
Paul Anantharajah TambyahQ47499195
Otfried KistnerQ93004381
Sandor FritschQ104744986
Hartmut J EhrlichQ104745018
P Noel BarrettQ104745030
P2093author name stringMarkus Müller
Eva Maria Pöllabauer
Maikel V W van der Velden
Alexandra Löw-Baselli
Borislava G Pavlova
Friedrich Maritsch
Greg Berezuk
Helen M L Oh
Markus Zeitlinger
P433issue7
P407language of work or nameEnglishQ1860
P304page(s)1113-1118
P577publication date2009-10-01
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleA cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
P478volume200

Reverse relations

cites work (P2860)
Q30418715A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination
Q30224624A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate
Q30359896A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.
Q30419799A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory
Q36086664A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses
Q30386068A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.
Q38056159A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.
Q30224538A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].
Q30224497Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
Q28084739Cell culture-based influenza vaccines: A necessary and indispensable investment for the future
Q30419591Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production
Q44278166Clinical development of a Vero cell culture-derived seasonal influenza vaccine
Q30382947Continuous cell lines as a production system for influenza vaccines.
Q57158300Correlates of Protection Against Influenza
Q83880292Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains
Q30226730Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
Q30409570Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion
Q30353991Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
Q30395944Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Q27000896H5N1 vaccines in humans
Q28741304H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model
Q30424002Immunogenic and protective properties of the first Kazakhstan vaccine against pandemic influenza A (H1N1) pdm09 in ferrets.
Q30372141Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.
Q42178340Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial
Q30362811Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.
Q30367695Influenza vaccines: a moving interdisciplinary field.
Q30402018MF59 adjuvant: the best insurance against influenza strain diversity
Q30411859New technologies for influenza vaccines
Q30383323On the press coverage on the Austrian allocation of vaccine against the pandemic influenza A/H1N1
Q30368247Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Q30414998Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Q30420569Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine
Q30381595Refining the approach to vaccines against influenza A viruses with pandemic potential.
Q44197848Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013.
Q37918307Return of inactivated whole-virus vaccine for superior efficacy
Q30210481Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients
Q34073541Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
Q37919896The future of cell culture-based influenza vaccine production
Q30429058Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development

Search more.